Purchase this article with an account.
L.B. Cantor, D. Wudunn, A. Cortes, J. Hoop, S. Knotts; Ocular Hypotensive Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Patients with Glaucoma or Ocular Hypertension . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4369.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the IOP-lowering efficacy of bimatoprost and travoprost for the treatment of glaucoma and ocular hypertension. Methods: Randomized, double-masked, parallel-group clinical trial. After completing a washout from all glaucoma medications, patients (n=28) were randomized to bimatoprost or travoprost for 6 months. Visits were at baseline, week 1, and months 1, 3, and 6. IOP was measured at 9 AM at each visit and also at 1 and 4 PM at baseline and months 3 and 6. The study is ongoing and the initial pilot data are presented here. Results: Most patients were Caucasian [93%, (13/14) in the bimatoprost group, vs. 71% (10/14) in the travoprost group, P=.326] and female [71% (10/14) in the bimatoprost group vs. 50% (7/14) in the travoprost group, P=.246]. There was no significant between-group difference in mean age (58.6 years in the bimatoprost group, vs. 62.6 years in the travoprost group, P=.417). At the baseline visit, there were no significant between-group differences in IOP at 9AM, 1PM, or 4PM (P>.817). After 6 months of therapy, both medications provided significant mean reductions from baseline IOP at every time point (P<.007). Bimatoprost provided greater mean IOP reductions from baseline than travoprost at all diurnal measurements. Mean IOP reductions ranged from 7.4 mm Hg to 8.8 mm Hg (34% to 36%) with bimatoprost and from 4.6 mm Hg to 7.2 mm Hg (19% to 29%) with travoprost (P>.057). At every time point, patients were more likely to achieve low target pressures with bimatoprost than with travoprost. For example, 86% of bimatoprost patients achieved a target < 17 mm Hg at 9 AM, compared with 50% of travoprost patients. At the end of the day, at 4 PM, a target of < 17 mm Hg was reached by 85% of bimatoprost patients, compared with 64% of travoprost patients. Ocular redness was the most commonly reported adverse event in each treatment group. Conclusions: Both bimatoprost and travoprost effectively lowered IOP in patients with glaucoma or ocular hypertension. Bimatoprost provided larger mean IOP reductions than travoprost. More patients achieved low target pressures with bimatoprost than with travoprost. These findings are being further evaluated in an ongoing multicenter clinical trial.
This PDF is available to Subscribers Only